Retinoblastoma is the most common intraocular cancer in children. While the primary tumor can often be treated by local or systemic chemotherapy, metastatic dissemination is generally resistant to therapy and remains a leading cause of pediatric cancer death in much of the world. In order to identify new therapeutic targets in aggressive tumors, we sequenced RNA transcripts in five snap frozen retinoblastomas which invaded the optic nerve and five which did not. A three-fold increase was noted in mRNA levels of ACVR1C/ALK7, a type I receptor of the TGF-β family, in invasive retinoblastomas, while downregulation of DACT2 and LEFTY2, negative modulators of the ACVR1C signaling, was observed in most invasive tumors. A two-to three-fold increase in ACVR1C mRNA was also found in invasive WERI Rb1 and Y79 cells as compared to non-invasive cells in vitro. Transcripts of ACVR1C receptor and its ligands (Nodal, Activin A/B, and GDF3) were expressed in six retinoblastoma lines, and evidence of downstream SMAD2 signaling was present in all these lines. Pharmacological inhibition of ACVR1C signaling using SB505124, or genetic downregulation of the receptor using shRNA potently suppressed invasion, growth, survival, and reduced the protein levels of the mesenchymal markers ZEB1 and Snail. The inhibitory effects on invasion, growth, and proliferation were recapitulated by knocking down SMAD2, but not SMAD3. Finally, in an orthotopic zebrafish model of retinoblastoma, a 55% decrease in tumor spread was noted (p = 0.0026) when larvae were treated with 3 µM of SB505124, as compared to DMSO. Similarly, knockdown of ACVR1C in injected tumor cells using shRNA also resulted in a 54% reduction in tumor dissemination in the zebrafish eye as compared to scrambled shRNA control (p = 0.0005). Our data support a role for the ACVR1C/SMAD2 pathway in promoting invasion and growth of retinoblastoma.
Introduction
Retinoblastoma is the most common pediatric intraocular cancer, affecting approximately 300 children per year in the United States and causing approximately 4000 deaths annually worldwide [1] . In Saudi Arabia, according to the Cancer Incidence Report 2014, it accounts for 3.3% of childhood cancers and is listed among the top ten most common cancers in Saudi children at 5.7% among girls and 1.5% among boys. While the primary tumor can often be successfully treated by local and/or systemic chemotherapy, extraocular dissemination through the optic nerve into the central nervous system (CNS) or through the choroid into the bloodstream, represents a serious clinical complication. Metastatic progression occurs in cases which are particularly aggressive or not treated promptly, and usually appears within the first year after diagnosis [1] . Metastases in the CNS or in distant organs, such as bone and bone marrow, are resistant to current therapies and generally fatal [2, 3] . CNS involvement is the most common complication, with nearly 100% mortality [1] . The molecular factors driving metastatic spread are not well understood, thus there is an urgent need to elucidate the molecular drivers responsible for retinoblastoma invasion into the optic nerve and other sites, in order to establish new therapeutic targets.
Here we show that Activin A receptor type 1C (ACVR1C), also known as activin-like kinase receptor 7 (ALK7), as well as downstream signaling by homologues of the Drosophila protein, mothers against decapentaplegic (Mad) and the Caenorhabditis elegans protein Sma, family member 2 (SMAD2) plays an important role in promoting retinoblastoma dissemination. ACVR1C/ALK7 is a type I receptor of the TGF-β (transforming growth factor-beta) family, which binds Nodal, Activin A/B, and GDF3 (growth and differentiation factor 3), and is predominantly expressed in the CNS, colon and pancreas [4] .
Members of the TGF-β superfamily include TGF-β1, bone morphogenic protein (BMP), Nodal, Activin A/B, and GDF, which are known to control many physiological processes, including proliferation, differentiation, wound healing, and immune responses [5] . TGF-β signaling regulates tumor growth and invasion in a number of contexts [6] [7] [8] . Nodal and Activin cytokines both bind to ACVR1B (ALK4) and ACVR1C (ALK7) receptors, which have intrinsic serine/threonine kinase activities in their cytoplasmic domains, inducing phosphorylation and activation of the SMAD2/3/4 complex, which translocates into the nucleus where it binds SMAD-binding elements (SBE) to activate gene transcription [9] . Activin, Nodal, and TGF-β ligands share the downstream effectors SMAD2 and SMAD3, thus they can have similar functions, but they often display distinct tissue expression patterns. Aberrant re-expression of Nodal, Activin, and TGF-β signaling has a prominent role in tumorigenesis and metastasis for melanoma, breast, prostate, and pancreatic cancers, where levels of Nodal are directly proportional to tumor grade [9] [10] [11] . Activin A also promotes anchorage-independent growth, epithelial-to-mesenchymal transition (EMT), invasion and stemness of breast cancer cells by SMAD-dependent signaling [12] . Prior studies have thus established a role for Nodal/Activin/TGF-β pathway in promoting a stem/progenitor-like phenotype in several tissues, and inducing tumor growth and metastasis. Here we found that inhibition of this signaling potently suppressed a metastatic phenotype in retinoblastoma cells, both in vitro and in vivo.
Results
Next-generation RNA sequencing data Gene expression differences between five non-invasive (cases 1-5) and five invasive (cases 6-10) retinoblastoma specimens, whose clinical characteristics are summarized in Table S1 , were quantified. Optic nerve invasion was identified by magnetic resonance imaging (MRI) and confirmed by microscopic analysis of resected tumors. Representative MRI images with either no invasion, limited retrolaminar invasion or extensive dissemination in the optic nerve are shown in Fig. 1a -c, respectively. Using RNA sequencing, we found 153 genes whose mean expression was altered by more than 2-fold in the invasive cohort: 33 were upregulated and 120 were downregulated. The genes which showed an increase of two-fold or more are listed in Table 1 and Figure S1 . The most upregulated gene in the invasive cohort was ADCYAP1 (adenylate cyclase-activating polypeptide 1), whose expression increased almost 60 fold. The ADCYAP1 gene product (PACAP, pituitary adenylate cyclase-activating polypeptide) is normally expressed in the CNS, including retinal ganglion cells, and in most peripheral organs [13] . The most upregulated genes previously associated with tumor spread included DLX6 (distal-less homeobox 6), associated with metastatic progression in breast cancer [14] , and MMP12 (matrix metallopeptidase), involved in promoting invasion in lung and nasopharyngeal carcinoma [15, 16] . In addition we found two-fold upregulation of IQGAP3 (IQ motif containing GTPaseactivating protein 3), an effector of Rac/Cdc42, which promotes cell migration/invasion by interacting with small GTPase proteins [17, 18] .
ACVR1C (ALK7) levels were induced in all cases of invasive retinoblastoma (Fig. 1d ). ACVR1C is a type I receptor of the TGF-β family, which binds Nodal, Activin A/B, and GDF3 [9] . Furthermore, DACT2 (dishevelled binding antagonist of beta catenin 2), a negative regulator of the Nodal/TGF-β signaling [19] , was downregulated more than 28-fold on average in the invasive cohort, while LEFTY2 (left-right determination factor 2), a natural inhibitor of the Nodal/TGF-β pathway [20] , was reduced about 10-fold on average in the invasive group (Fig. 1d ).
ACVR1C was also induced in invasive WERI Rb1 and Y79 retinoblastoma cells in vitro. In cells that migrated through a filter pre-coated with Matrigel, ACVR1C mRNA levels were two-fold higher in both WERI Rb1 (p = 0.01) and Y79 cells (p = 0.0027) as compared to those which did not move from the insert (Fig. 1e ). b Axial T1-weighted post contrast, the fat-suppressed image of case #8: retinoblastoma with post laminar optic nerve invasion (arrowhead). c Axial post-contrast T1WI, the fat-suppressed image of case #9: retinoblastoma which diffusely infiltrated the sclera and the optic nerve. d The mRNA levels of ACVR1C were significantly increased in all five invasive cases, while those of DACT2 and LEFTY2 were significantly decreased in most of the invasive cases. Expression levels were obtained from the RNA-seq analysis. Probability of differential expression: PPDE = 0.814 (ACVR1C); PPDE = 0.995 (DACT2); PPDE = 0.892 (LEFTY2). e ACVR1C mRNA levels were significantly increased in invasive WERI Rb1 and Y79 cells, as compared to non-invasive cells. Transwell invasion assay was used to separate the invasive cells, present in the lower side of a Matrigel-coated filter, from the non-invasive, present inside of the insert, after 72 h of incubation, following a previous procedure [54] Several reductions in gene expression were also identified in invasive retinoblastomas (Table 2, Figure S1 ). The most downregulated gene was CRABP1 (cellular retinoic acid binding protein 1), which regulates differentiation and is considered a candidate tumor suppressor in esophageal carcinoma [21] . Other genes whose expression was significantly reduced in the invasive tumors include: GFAP (glial fibrillary acidic protein) and RHO (rhodopsin), both markers of cell differentiation in retinoblastoma cells [22] , and NGFR (nerve growth factor receptor). In addition, DACT2, a negative regulator of the Nodal and WNT signaling [19] , was reduced 28-fold in the invasive cohort.
Components of the ACVR1C/SMAD2 pathway are expressed in retinoblastoma cells
The ACVR1C receptor as well as its ligands, Nodal, Activin A/B, and GDF3, were expressed at the mRNA level in six retinoblastoma-derived cell lines: WERI Rb1, Y79, and RB143 (patient-derived primary lines which grow in the presence of serum), HSJD-RBT-1 and HSJD-RBT-2 (patient-derived primary lines which grow in serum-free medium), and HSJD-RBVS-10, a serum-free line derived from tumor seeding in the vitreous ( Fig. 2a-e ). The ligands and receptors expressed in the retinoblastoma cells appear to activate downstream SMAD signaling, with phosphorylation of SMAD2, the main downstream effector of Nodal/ TGF-β pathway, in all retinoblastoma lines analyzed (Fig.   2f ). In contrast, SMAD3 was expressed only in WERI Rb1 and Y79, but no phosphorylation was detected in any retinoblastoma line (Fig. 2f ). We also found elevated protein expression of Nodal and GDF3 ligands in HSJD-RBT-2, WERI Rb1, and Y79, as opposed to HSJD-RBVS-10 and RB143, which expressed lower protein levels of these ligands (Fig. 2f ). Stimulated PANC-1 cells were used as positive controls for these antibodies ( Figure S2 ). Nodal was expressed mostly in the cytosol and cell membrane in WERI Rb1 and Y79, as determined by immunofluorescence ( Fig. 2g ).
Pharmacological blockade of the ACVR1C/SMAD2 pathway represses growth and invasion in retinoblastoma cells
Pharmacological inhibition of the ACVR1C receptor using SB505124, a selective inhibitor of ALK4/5/7 receptors [23] , significantly reduced growth (Fig. 3a, c, e ) and invasion ( Fig. 3b, d , f) of cultured retinoblastoma cells in a dose-dependent manner. In WERI Rb1 cells, growth was potently suppressed, starting at 2 µM after 3, 5, and 7 days of treatment ( Fig. 3a) . Y79 growth was almost completely suppressed at concentrations ≥1 µM ( Fig. 3c ), while HSJD-RBVS-10 cells were somewhat less responsive to SB505124-mediated growth inhibition ( Fig. 3e ). Nevertheless, SB505124 potently suppressed invasion of all three lines in a dose-dependent manner, as found by transwell invasion assay, with more than 70% inhibition in the ability of the cells to invade through a Matrigel-coated filter at concentrations ≥3 µM (Fig. 3b, d, f) . The effects on growth and invasion were paralleled by a dose-dependent inhibition in SMAD2 phosphorylation upon treatment with SB505124 at 0.5, 1, 2, 3, 4, 8 µM for 4 days (Fig. 4a-c) . SB505124 did not modify phosphorylation of SMAD3, which was minimal in these lines. However, we observed a dose-dependent decrease in the total levels of SMAD3 in WERI Rb1 and Y79 (Fig. 4a, b , bottom panel).
Interestingly, the reduction in invasion also correlated with a dose-dependent decrease in protein levels of the EMT markers ZEB1 (zinc finger E-box binding homeobox 1) and Snail, as found by western blot in all three retinoblastoma lines examined (Fig. 4a-c) .
Some of the reduced growth in viable cell mass was due to decreased survival of cells, as treatment with SB505124 also induced a dose-dependent increase in cleaved PARP, a marker of late apoptosis (Fig. 4a-c) . The induction of apoptosis was also confirmed by cleaved caspase-3 assay in WERI Rb1, Y79 (Fig. 4d, e ) and in HSJD-RBVS-10 (data not shown). These findings indicate that the ACVR1C/ SMAD2 pathway promotes growth, survival, and invasive properties in retinoblastoma cells.
Genetic downregulation of the ACVR1C/SMAD2 pathway inhibits invasion and proliferation in Y79 cells
To further establish the role of the ACVR1C receptor in promoting invasion and growth of retinoblastoma, we genetically inhibited its expression by short hairpin RNA (shRNA). Two target sequences were effective in reducing ACVR1C mRNA levels by more than 80% (p = 0.007, Fig.  5a ). This reduction was accompanied by approximately 70% inhibition in invasion, as determined by transwell invasion assay (Fig. 5b) , with a significant downregulation of mRNA and protein levels of Snail (Fig. 5c, d) , and in the decreased protein levels of ZEB1 (Fig. 5d ). SMAD2 phosphorylation was also reduced in cells expressing ACVR1C shRNA as compared to scrambled shRNA, supporting this downstream effector as a potential mediator of ACVR1C signaling in retinoblastoma. Y79-GFP cells expressing ACVR1C shRNA showed high levels of cleaved PARP as compared to cells transduced with scrambled shRNA or parental line (Fig. 5d ) indicating reduced survival. We then assessed the ability of these cells to grow and proliferate, by performing respectively CCK-8 and Ki67 assays, respectively. Growth was potently reduced in ACVR1C shRNA-expressing cells as compared to scrambled shRNA (Fig. 5e ). We also found 40-50% reduction in the percentage of Ki67-positive cells using both shRNAs as compared to scrambled control, confirming a decrease in proliferation upon reduction of ACVR1C expression (p < 0.0001, Fig. 5f ).
To address the role of SMAD2 and SMAD3 in mediating the downstream effects of ACVR1C, we repressed the expression of SMAD2 or SMAD3 by shRNA in Y79 cells. We used three target sequences for each gene, and found that all of them effectively reduced the protein levels of SMAD2 ( Figure S3a ) and SMAD3 ( Figure S4a ). This reduction was paralleled by about 80% decrease in invasion, when cells were transduced with shSMAD2 ( Figure S3b ), but no difference was observed when SMAD3 was knocked down ( Figure S4b ). Likewise, proliferation and growth were significantly reduced when SMAD2 expression was Fig. 2 Expression of ACVR1C/SMAD2 pathway components in retinoblastoma lines. The mRNA levels of ACVR1C receptor (a) and ligands (b-e) in multiple retinoblastoma lines were determined by qPCR. P-values were calculated using one-way analysis of the variance (ANOVA), with post-hoc Tukey's test in the table. Levels of phospho-and total SMAD2/3 proteins, Nodal and GDF3 ligands in retinoblastoma lines were evaluated by Western blot (f), using β-actin as loading control. Pancreatic cancer cell line PANC-1, treated with TGF-β1 at 10 ng/mL for 2 h, was used as positive control for phospho-SMAD3 antibody. Nodal expression was determined in WERI Rb1 and Y79 cells by immunofluorescence (g), using anti-Nodal antibody (red). Nuclei were stained with DAPI (blue). PANC-1 cells were used as positive control inhibited ( Figure S3c, d) , as opposed to SMAD3 downregulation, which did not inhibit either replication or growth, as found by Ki67 and CCK-8 assay, respectively ( Figure S4c, d ). Since we observed that only the knockdown of SMAD2, but not SMAD3, recapitulated the inhibitory effects on invasion, growth, and proliferation, associated with lowered levels of ACVR1C receptor, we believe that the pathway induced by ACVR1C signaling is mediated downstream mostly by SMAD2.
Treatment with recombinant Nodal does not affect invasion, proliferation, and growth in WERI Rb1 and Y79 cells
To address the role of ACVR1C ligands in regulating growth and invasion in retinoblastoma, we stimulated WERI Rb1 and Y79 cells with human recombinant Nodal. Surprisingly, we did not observe any further increase in SMAD2 phosphorylation upon treatment with Nodal at 100, Figure S5a ). Similarly, invasion, proliferation, and growth were not significantly modified by Nodal treatment in these cells ( Figure   S5b-d) . Thus the relatively high levels of Nodal present in WERI Rb1 and Y79 at steady state ( Fig. 2f-g ) may already maximally induce tumorigenic effects.
Pharmacological and genetic inhibition of the ACVR1C/SMAD2 signaling reduces retinoblastoma cell dissemination in vivo in zebrafish
Y79 cells, labeled with GFP, were injected intravitreally in the zebrafish eye at 2 days post-fertilization (dpf). Zebrafish larvae (n = 12) were then treated with DMSO or 3 µM of SB505124 for 4 days. Cells were monitored longitudinally by confocal microscopy at 1 and 4 days post-injection (dpi). No significant increase in cell number was seen over this time period, however we observed that the Y79-GFP cells spread from the initial injection site and some had migrated outside the eye at 4 dpi. Minimum bounding spheres (MBS) were used to outline the extent of tumor dissemination, and are highlighted in red (Fig. 6a) . A significant increase in retinoblastoma cell spread over time was observed in DMSO control larvae (p = 0.0082), but not in those treated with SB505124 (p = 0.59; Fig. 6b ). Because no significant change in cell number was identified over this time, the 55% reduction in MBS diameter fold change when larvae were treated with 3 µM of SB505124 for 4 days as compared to DMSO was most likely due to effects on tumor invasion rather than proliferation or survival (p = 0.0026; Fig. 6c ).
Genetic inhibition of the pathway showed similar results. Y79-GFP cells expressing ACVR1C shRNA or scrambled shRNA were injected intravitreally in zebrafish larvae and monitored longitudinally by confocal microscopy at 1 and 4 dpi ( Figure S6a ). We found a significant increase in cell spread in the cohort injected with Y79-GFP expressing scrambled shRNA (p = 5.66 × 10 −5 ) but not in those with ACVR1C shRNA (p = 0.29) as measured by MBS diameter (Figure S6b) . A significant 54% reduction in MBS diameter fold-change, indicative of reduction in tumor dissemination, was observed in the cohort injected with Y79-GFP cells expressing ACVR1C shRNA, as compared to scrambled shRNA (p = 0.0005; Figure S6c ). These in vivo findings further support the concept that targeting the ACVR1C/ SMAD2 pathway may be effective in treating retinoblastoma invasion.
DIscussion
Retinoblastoma causes significant morbidity including loss of vision, and when metastatic usually leads to death, as metastases are generally resistant to current chemotherapeutic regimens [24, 25] . Although extraocular retinoblastoma is rare in the Western countries, it is more frequent in the developing world. In low-income countries of Asia and Africa, the extraocular disease is present in 20-50% of all retinoblastoma cases [26, 27] and is almost always fatal. Here we focused on the role of ACVR1C/SMAD2 signaling in promoting invasion and growth in retinoblastoma, as we found that the mRNA levels of ACVR1C (ALK7), a type I serine/threonine kinase receptor of the TGF-β family, were increased in all invasive retinoblastoma specimens that we have analyzed by next-generation RNA sequencing. Downregulation of natural inhibitors of ACVR1C/ SMAD2 signaling, such as DACT2 and LEFTY2, was also observed in most of the invasive cases.
The ACVR1C receptor binds to members of the TGF-β superfamily, such as Nodal, Activin A/B, and GDF3, leading to activation, through serine-threonine phosphorylation, of SMAD2 and SMAD3 downstream effectors. The cofactor SMAD4 combines with the activated form of SMAD2/3, forming a complex which translocates in the nucleus, activating gene transcription [5, 9] . Activin and Nodal are known to maintain pluripotency in human embryonic stem cells by controlling Nanog expression, and disruption of these pathways results in cell differentiation [28] .
Growing evidence has also shown that TGF-β, Nodal, and Activin signaling regulates tumor progression and metastasis [29] . Nodal is highly expressed in metastatic melanoma, but not in normal melanocytes or non-invasive melanoma [30] , and antibodies against Nodal have been shown to induce apoptosis in melanoma cells [31] . Nodal is also expressed in breast cancer in correlation with disease progression and is required to induce, through ERK signaling, a tumorigenic phenotype in triple-negative breast cancers [11] . Conversely, overexpression of ACVR1C has been associated with decreased growth and adhesion in breast cancer [32] , while downregulation of this receptor has been linked to poor prognosis and metastasis in pancreatic adenocarcinoma [9] . However, activating mutations in a receptor of the same family, ACVR1 (ALK2), specific for bone morphogenetic protein (BMP), are present in 33% Fig. 4 Pharmacological inhibition of the ACVR1C/SMAD2 pathway induces apoptosis and inhibits the expression of EMT markers in retinoblastoma cells. a-c Phosphorylation of SMAD2 was reduced in a dose-dependent manner in WERI Rb1 (a), Y79 (b), HSJD-RBVS-10 (c) cells treated with SB505124 for 4 days at the indicated doses, as found by western blot. Induction of cleaved PARP, indicative of apoptosis, and reduction in Snail and ZEB1 protein levels were also observed, starting at the dose of 2 μM. No phosphorylation of SMAD3 was detected in these lines, while a dose-dependent decrease in the protein levels of SMAD3 was observed in WERI Rb1 and Y79 (a, b,  bottom panel) . PANC-1 cells treated with TGF-β1 at 10 ng/mL for 2 h were used as positive control for phospho-SMAD3 antibody. d, e Treatment with SB505124 for 3 days significantly increased apoptosis at 4 and 8 µM in WERI Rb1 (d) and at 2, 4, 8 μM in Y79 (e), compared to DMSO, as determined by immunofluorescence assay using an antibody specific for cleaved caspase-3 (red). P-values were calculated using two-sided Student t-test vs DMSO-treated cells. Data are presented as mean ± SD. Microphotographs in the right part of the panels are representative images of the immunofluorescence staining. Nuclei were stained with DAPI (blue) were dramatically reduced in cells expressing ACVR1C shRNAs as compared to scrambled shRNA, while the apoptotic marker cleaved PARP was increased, as found by western blot (d). Growth was reduced by more than 90% in Y79 cells expressing two different ACVR1C shRNAs, compared to scrambled shRNA, as found by CCK-8 growth assay (e). The percentage of Ki67-positive cells was reduced from 40 to 50% in cells transduced with two different ACVR1C shRNAs, compared to scrambled shRNA, as found by Ki67 proliferation assay (f) of Diffuse Intrinsic Pontine Glioma (DIPG), a highly invasive pediatric brain tumor [33] . Activin, another ligand of ACVR1C receptor, also plays a key role in cancer biology. It is upregulated in breast cancer, as indicated by the significant increase in the levels of Activin A and phospho-SMAD2-3 in advanced breast cancer as compared to normal tissues [12] . In addition, prior studies have linked Nodal/Activin signaling to an invasive phenotype in several human cancers. In breast cancer, Nodal promotes EMT via SMAD2/3 pathway, by inducing Snail and Slug gene transcription [34] . In esophageal carcinoma, Activin A is associated with invasion and poor prognosis, through induction of N-cadherin [35] . We directly investigated the functional role of ACVR1C/ SMAD2 in the regulation of invasion and overall growth in retinoblastoma lines derived from primary tumors (WERI Rb1 and Y79), or vitreous seeds (HSJD-RBVS-10), using both a pharmacological and a genetic approach to suppress the pathway. We found that inhibition of ACVR1C/ SMAD2 pathway, using SB505124, a selective inhibitor of ALK4/5/7 receptors [23] , or downregulation of ACVR1C or SMAD2 by shRNAs, strongly suppressed the invasive properties of retinoblastoma cells both in vitro and in vivo. In parallel, we observed reductions in overall growth as well as proliferation, indicating a role for the ACVR1C/SMAD2 pathway in sustaining multiple aspects of retinoblastoma pathobiology. Importantly, using an orthotopic model of retinoblastoma invasion in zebrafish, we confirmed in vivo that blockade of the ACVR1C-mediated pathway produced more than 50% inhibition in the ability of Y79-GFP cells to disseminate.
In contrast, SMAD3 was not phosphorylated in the retinoblastoma lines that we analyzed, and its downregulation did not modify invasion, growth, or proliferation in Y79 cells. It is not clear why SMAD2, but not SMAD3, is activated in these tumors. Stimulation of WERI Rb1 and Y79 cells with exogenous TGF-β1 ligand did not result in SMAD3 phosphorylation (data not shown). Analysis of 36 cases of retinoblastoma included in the Pediatric Pan-Cancer group (DKFZ-German Cancer Consortium, 2017) using CBioPortal (http://www.cbioportal.org) did not identify alterations in SMAD3 or ACVR1C, which might have modulated activation of SMAD3. However, it has been shown in some non-neoplastic settings that SMAD2 and SMAD3 can be differentially activated by TGF-β family ligands [36, 37] . The issue of the selective phosphorylation of SMAD2 but not SMAD3 by the ACVR1C-mediated pathway in retinoblastoma cells is intriguing and worthy of further investigation.
We believe that the inhibitory effects on invasion may be mediated at least in part by the downregulation of EMT factors, such as ZEB1 and Snail, as we found a dramatic reduction in their protein levels upon pharmacological or genetic blockade of ACVR1C-mediated signaling. It is known that these EMT factors promote invasion and metastasis in other tumor models [38] and their expression is regulated, among other mechanisms, by SMAD2 signaling [34, 39, 40] . Previous studies have also shown that inactivation of RB protein contributes to tumor progression in breast cancer through induction of ZEB1 expression [41, 42] , which could in part explain the elevated protein levels of ZEB1 that we observed in the retinoblastoma lines.
The signaling initiated by Nodal and Activin regulates retinal development, supporting retinal progenitor specification from mouse embryonic stem cells [43] , and modulating differentiation of WERI Rb1 cells into retinal neurons [22] . Activin blocks retinal regeneration from the retinal pigmented epithelium in chicken embryos [44] , and inhibits growth in retinoblastoma, inducing differentiation of Y79 cells [45] . It is known that Activin often antagonizes the effects of Nodal, and the ligands that activate SMAD2/3 pathway can have opposing effects depending on the cellular type and context [46] . Further investigation is warranted to more closely interrogate the functional roles of ACVR1C ligands in regulating retinoblastoma invasion and growth.
Materials and methods

Clinical specimens and RNA-seq analysis
Ten snap frozen retinoblastoma specimens were analyzed by RNA-seq (low input, non-strand specific). Samples were divided in five non-invasive (case 1-5: prelaminar, n = 4, no optic nerve invasion, n = 1) and five invasive (case 6-10: retrolaminar, n = 4; intralaminar, n = 1). Four cases with optic nerve invasion and two without also showed focal (<3 mm) choroidal invasion, but none had massive choroidal invasion. Anterior segment invasion was present in two of the invasive cases. The clinical characteristics of the cases are reported in Table S1 . These cases were identified through review of pathology and tumor bank records at King Khaled Eye Specialist Hospital (KKESH), Riyadh, Saudi Arabia. MRI examination was performed to confirm optic nerve invasion ( Fig. 1a-c ). Only tumors with tissue snap-frozen at the time of surgery were used in this study. Two ophthalmic pathologists (Drs. Deepak Edward and Azza Maktabi) reviewed the histopathological slides to confirm the presence of retinoblastoma and the extent of invasion.
Cell cultures, plasmids, and chemical reagents
WERI-Rb1 [47] and Y79 [48] human retinoblastoma cells lines were obtained from American Type Culture Collection (ATCC, Manassas, VA). RB143 was obtained from Kerafast, Inc. [49] . These lines were cultured in RPMI-1640 supplemented with 50 IU/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine and 10% heat-inactivated fetal bovine serum (FBS), at 37°C in a humidified 5% CO 2 atmosphere. HSJD-RBT-1, HSJD-RBT-2, patient-derived primary lines which grow in serum-free medium, and HSJD-RBVS-10, a serum-free line derived from tumor seeding in the vitreous, kindly provided by Dr. Carcaboso, were maintained in tumor stem medium, supplemented with B-27 (Thermo Fisher, Waltham, MA), recombinant EGF, FGF, PDGF-AA/BB (Peprotech, Rocky Hill, NJ) and heparin solution (Sigma-Aldrich, St. Louis, MO), as previously described [50] . PANC-1 cells (pancreatic cancer line), kindly provided by Dr. Michael Goggins (Johns Hopkins University), were used as a positive control for SMAD3 phosphorylation, upon treatment for 2 h with TGF-β1 (Peprotech) at 10 ng/mL. All the cell lines were tested periodically for mycoplasma contamination and STR profiling. pLKO.1 transfer vectors containing short hairpin RNA (shRNA) targeting ACRV1C, SMAD2, or SMAD3 mRNA (sequences are described in Table S2 ) were purchased from Thermo Fisher. Plasmidic DNA was isolated using PureLink® HiPure Plasmid Midiprep kit (cat. # K210014, Invitrogen, Carlsbad, CA). Lentiviral particles carrying these constructs were prepared using HEK293T as previously described [49] . Puromycin (1 µg/mL) was used to select cells expressing the transfer vector. Scrambled shRNAs were used as control. SB505124, a selective inhibitor of ALK4/5/7 receptors [23] , was purchased from MedChemExpress, Monmouth Junction, NJ (cat. # HY-13521) and dissolved in DMSO at the stock concentration of 10 mM, following manufacturer's protocol. Recombinant human Nodal ligand was purchased from R&D Systems Inc., Minneapolis, MN (cat. # 3218-ND-025).
RNA extraction and quantitative real-time PCR
RNeasy mini kit (Qiagen, Germantown, MD) was used to perform RNA extraction from retinoblastoma cell lines, with on-column DNA digestion carried out with RNase-free DNase kit (Qiagen), to eliminate genomic DNA. Quantitative real-time PCR (qPCR) for ACVR1C/SMAD2 pathway components was carried out as previously described [51] , with primer sequences listed in Table S3 . Each experiment was performed three times and all reactions were carried out in triplicates in iQ5 Multicolor real-time PCR detection system (Bio-Rad, Hercules, CA), using SYBR Green (Applied Biosystems, Foster City, CA) as fluorescent dye; β-actin mRNA levels were used to normalize the results.
RNA-seq analysis
Ten snap frozen retinoblastoma specimens were analyzed by RNA-seq (low input, non-strand specific). For our low input RNA library preparation workflow, the quality of total RNA was measured by the Agilent Bioanalyzer (Santa Clara, CA) utilizing a RNA Pico chip to generate a RIN score. High-quality RNA (>7.0 RIN) was used to generate a library for sequencing. Starting with 500 pg-100 ng of total RNA, generation of cDNA was prepared as directed in the Nugen Ovation RNA-Seq System V2 Sample Preparation Guide. After purification of the cDNA was complete, construction of the sequencing library was prepared as directed in the Illumina TruSeq DNA sample preparation guide. Fragmentation was performed on the Covaris S2. PCR was performed to selectively enrich DNA fragments which have adaptor molecules and to amplify the amount of the library itself. Libraries were run on a High Sensitivity chip using the Agilent Bioanalyzer to assess size distribution and overall quality of the amplified library. Quantification of the libraries was performed by qPCR with the Kappa Library Quantification Kit or by the Agilent Bioanalyzer and equimolar concentrations of each library were pooled together. Cluster generation and sequencing was performed on an Illumina HS2500 platform for a 100 bp × 100 bp, paired-end sequencing utilizing the TruSeq Rapid PE Cluster Kit and TruSeq Rapid SBS Kit (200 cycles) respectively. Data analysis was performed using Integrative Genomics Viewer (IGV) software [52] . All RNA-seq data generated during this study are included in this article (and its supplementary information files).
Western blotting
The protein levels of total and phospho-SMAD2/3, ZEB1, Snail, and cleaved poly (ADP-ribose) polymerase (PARP) were evaluated by western blot in retinoblastoma cells, with β-actin used as a loading control. Proteins were extracted using TNE lysis buffer, as previously described [49] . 4-12% SDS-polyacrylamide gel electrophoresis (Invitrogen), was used to separate equal amounts of proteins, which were then transferred on a nitrocellulose membrane (Invitrogen) and incubated for 1 h in blocking solution containing 5% dried milk in TBS with 0.1% Tween 20 (TBS-T). Membranes were incubated with the primary antibodies overnight in blocking solution at 4°C. The following primary antibodies were used: total and phospho-SMAD2/3 (in rabbit, 1:1000, Cell Signaling Technology, SMAD2/3 sampler kit #12747, Danvers, MA), ZEB1 (in rabbit, 1:2000, Sigma-Aldrich, # HPA027524, St. Louis, MO), Snail (in mouse, 1:1000, Cell Signaling Technology, #3895, Danvers, MA), cleaved poly (ADP-ribose) polymerase (PARP), cleaved PARP at Asp 214 (in rabbit, 1:1000, Cell Signaling Technology, #5625), Nodal (in mouse, 1:800, Sigma-Aldrich, #SAB1404135), GDF3 (in mouse, 1:500, Sigma-Aldrich, #SAB1406848), β-actin (in mouse, 1:500, Santa Cruz Biotechnology, # sc-47778, Dallas, TX). Secondary antibodies bound to peroxidase and raised in mouse or in rabbit (1:3000, Cell Signaling Technology, #7074, #7076) were used to visualize protein bands. Enhanced chemiluminescence (ECL) was used as detection reagent (Perki-nElmer, Waltham, MA). each experimental condition. Statistical analyses were carried out with R 3.3.1 and RStudio 0.99.893. Student's t-test was used to calculate effect size between paired groups, with effect size, 95% confidence intervals (CI), and P-values provided.
